Skip to Content

And Just Like That, Juno Therapeutics Is Back in Business

Despite three deaths, a trial for a powerful cancer treatment has been cleared to resume.

In a rapid turnaround, biotech firm Juno Therapeutics has been given the green light to resume testing a promising cancer therapy that involves genetically engineering patients’ immune systems.

Last week, the U.S. Food and Drug Administration ordered Juno to halt its trial of the treatment after three patients died. The company said the deaths were not the result of the immune cells, which are modified outside the body before being injected back into a patient, but of a toxic reaction to a preconditioning drug used as part of the treatment. That compound, fludarabine, has been removed from the protocol.

Juno’s stock rebounded on the news, after it had plunged 30 percent last week when the trial was stopped. Whether the company will be able to beat competitors Kite Pharma and Novartis to market remains to be seen. Juno had been planning on seeking FDA approval in 2017.

Initial trials for Juno’s therapy, known as CAR-T, have produced remarkable results in patients with recurrent acute lymphoblastic leukemia—about eight in 10 patients saw their tumors disappear. But the treatment is risky, so the tests have been limited to patients facing long odds of survival.

(Read more: Endpoints, “Unexpected Deaths Put Promising Immunotherapy on Hold,” “Gene Therapy’s First Out-and-Out Cure Is Here,” “Biotech’s Coming Cancer Cure”)

Keep Reading

Most Popular

Geoffrey Hinton tells us why he’s now scared of the tech he helped build

“I have suddenly switched my views on whether these things are going to be more intelligent than us.”

Meet the people who use Notion to plan their whole lives

The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.

Learning to code isn’t enough

Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.

Deep learning pioneer Geoffrey Hinton has quit Google

Hinton will be speaking at EmTech Digital on Wednesday.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.